Systemic Mastocytosis – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Systemic Mastocytosis – Pipeline Review, H2 2019’, provides an overview of the Systemic Mastocytosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis

– The report reviews pipeline therapeutics for Systemic Mastocytosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Systemic Mastocytosis therapeutics and enlists all their major and minor projects

– The report assesses Systemic Mastocytosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Systemic Mastocytosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Allakos Inc

Arog Pharmaceuticals Inc

Blueprint Medicines Corp

Bristol-Myers Squibb Co

Deciphera Pharmaceuticals Inc

Seattle Genetics Inc

Stemline Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Systemic Mastocytosis – Overview

Systemic Mastocytosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Systemic Mastocytosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Mastocytosis – Companies Involved in Therapeutics Development

AB Science SA

Allakos Inc

Arog Pharmaceuticals Inc

Blueprint Medicines Corp

Bristol-Myers Squibb Co

Deciphera Pharmaceuticals Inc

Seattle Genetics Inc

Stemline Therapeutics Inc

Systemic Mastocytosis – Drug Profiles

AK-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avapritinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-263 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brentuximab vedotin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenolanib besylate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ripretinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tagraxofusp – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Systemic Mastocytosis – Dormant Projects

Systemic Mastocytosis – Discontinued Products

Systemic Mastocytosis – Product Development Milestones

Featured News & Press Releases

Nov 25, 2019: AB Science provides the summary of webcast with Key opinion leaders on Indolent Systemic Mastocytosis

Nov 06, 2019: Blueprint Medicines to present initial data from phase 2 PIONEER trial of Avapritinib in patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

Nov 04, 2019: AB Science will host a live webcast on indolent systemic mastocytosis on November 20, 2019

Oct 24, 2019: AB Science granted authorization to initiate phase 3 confirmatory study of Masitinib in indolent systemic mastocytosis

Aug 12, 2019: AB Science to present at two upcoming conferences in September 2019

Aug 05, 2019: AB Science provides an update on its masitinib clinical program

Jun 15, 2019: Blueprint Medicines presents updated EXPLORER trial data for Avapritinib in patients with systemic mastocytosis at 24th EHA Congress

Jun 04, 2019: AB Science is providing a summary of the web conference held on 4 June 2019

May 16, 2019: Blueprint Medicines announces data presentations at ASCO and EHA meetings from registration-enabling clinical trials of Avapritinib across multiple patient populations

Mar 27, 2019: Blueprint Medicines announces updates on regulatory submission plans and recent clinical progress of Avapritinib

Feb 19, 2019: Allakos announces positive phase 1 results with AK002 in Indolent Systemic Mastocytosis

Dec 02, 2018: Blueprint Medicines announces updated results from ongoing EXPLORER clinical trial of Avapritinib demonstrating broad clinical activity and significant symptom reductions in patients with systemic mastocytosis

Jun 15, 2018: Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity

May 17, 2018: Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis

Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Systemic Mastocytosis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Systemic Mastocytosis – Pipeline by AB Science SA, H2 2019

Systemic Mastocytosis – Pipeline by Allakos Inc, H2 2019

Systemic Mastocytosis – Pipeline by Arog Pharmaceuticals Inc, H2 2019

Systemic Mastocytosis – Pipeline by Blueprint Medicines Corp, H2 2019

Systemic Mastocytosis – Pipeline by Bristol-Myers Squibb Co, H2 2019

Systemic Mastocytosis – Pipeline by Deciphera Pharmaceuticals Inc, H2 2019

Systemic Mastocytosis – Pipeline by Seattle Genetics Inc, H2 2019

Systemic Mastocytosis – Pipeline by Stemline Therapeutics Inc, H2 2019

Systemic Mastocytosis – Dormant Projects, H2 2019

Systemic Mastocytosis – Discontinued Products, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports